ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to with your member or guest account, and visit the subscription center available under your account profile.

February 29, 2024

Congress passed a continuing resolution (CR) on February 29, 2024, that extends FY 2023 federal funding levels until March 22 for several government agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

February 28, 2024

The President's Cancer Panel published a report on February 28 on the National Cancer Plan that includes mention of seven American Society of Clinical Oncology (ASCO) programs that are contributing to the plan.

February 27, 2024

This month, Members of Congress sent letters to Senate leadership urging the Senate to use upcoming government funding legislation to address the Medicare physician payment cuts that took effect on January 1. With the March government funding deadlines coming up, the letter requests that the House and Senate work together to include provisions that provide stability to physician payments. The Association for Clinical Oncology urged House and Senate members to sign the letters and continues to monitor efforts to address Medicare physician cuts. 


February 26, 2024

The Federal Trade Commission and the U.S. Department of Health and Human Services issued a joint Request for Information on how group purchasing organizations’ and drug wholesalers’ practices are impacting the generic drug market. The Association for Clinical Oncology encourages stakeholders within the cancer community to comment to give federal agencies the perspective they need from across the myriad settings of cancer care. 


February 22, 2024

The American Society of Clinical Oncology (ASCO)’s new policy statement highlights the need for formalized efforts to address health-related social needs and outlines ways to address social determinants of health in cancer care.

February 16, 2024

On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. 

February 16, 2024

On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. 

February 16, 2024

On February 16, 2024, the Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.

February 14, 2024

On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.

February 14, 2024

The American Society of Clinical Oncology’s (ASCO) Serving the Underserved Task Force shared survey results that provide insight on oncology professionals’ experiences and strategies to support their work caring for underserved populations. 

February 13, 2024

The Centers for Medicare & Medicaid Services (CMS) has finalized prior authorization policy updates within Medicare Advantage (MA), Medicaid Managed Care and Fee for Service, Children’s Health Insurance Plans (CHIP) Managed Care and Fee for Service, and Qualified Health Plans (QHPs) on the Federally Facilitated Exchanges (FFEs). These changes come in response to the Association for Clinical Oncology (ASCO) and other stakeholder concerns that prior authorization processes limit beneficiary access to care in Medicare Advantage. 

February 13, 2024

The Alliance for Childhood Cancer held its 14th annual Action Days Feb.13-14, 2024, in Washington. ASCO is a proud member of the Alliance, a cohort of national patient advocacy groups, professional medical organizations, and scientific organizations dedicated to advancing research and policies to prevent cancer. During this year's Action Days, more than 200 advocates representing 34 states took part in 150 meetings on Capitol Hill.

February 6, 2024

Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer & Executive Vice President of the Association for Clinical Oncology (ASCO), will testify before the full House Committee on Ways and Means on the crisis of ongoing cancer drug shortages. Dr. Gralow will share ASCO members’ firsthand experiences managing clinical care in the face of severe shortages. She will also urge Congress to take action to help mitigate the problem.

January 29, 2024

CMS has released guidance on the billing requirements for G2211 to ensure that coding and billing staff know when to bill the code, the necessary documentation requirements, and the associated patient coinsurance and deductibles.

January 19, 2024

On January 19, 2024, the Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. This approval amends the indication previously granted under accelerated approval for patients with mUC with susceptible FGFR3 or FGFR2 alterations after prior platinum-containing chemotherapy.